EP3941467A4 - Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1 and/or pd-l1 inhibitor - Google Patents

Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1 and/or pd-l1 inhibitor Download PDF

Info

Publication number
EP3941467A4
EP3941467A4 EP20772952.6A EP20772952A EP3941467A4 EP 3941467 A4 EP3941467 A4 EP 3941467A4 EP 20772952 A EP20772952 A EP 20772952A EP 3941467 A4 EP3941467 A4 EP 3941467A4
Authority
EP
European Patent Office
Prior art keywords
ccr2
antagonist
inhibitor
combination therapy
chemokine receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20772952.6A
Other languages
German (de)
French (fr)
Other versions
EP3941467A1 (en
Inventor
James J. Campbell
Rajinder Singh
Jeffrey K. HARRISON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Chemocentryx Inc
Original Assignee
University of Florida
University of Florida Research Foundation Inc
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/358,329 external-priority patent/US20190269664A1/en
Application filed by University of Florida, University of Florida Research Foundation Inc, Chemocentryx Inc filed Critical University of Florida
Publication of EP3941467A1 publication Critical patent/EP3941467A1/en
Publication of EP3941467A4 publication Critical patent/EP3941467A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP20772952.6A 2019-03-19 2020-03-19 Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1 and/or pd-l1 inhibitor Pending EP3941467A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/358,329 US20190269664A1 (en) 2018-01-08 2019-03-19 Methods of treating solid tumors with ccr2 antagonists
US201962950780P 2019-12-19 2019-12-19
PCT/US2020/023722 WO2020191240A1 (en) 2019-03-19 2020-03-19 Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1 and/or pd-l1 inhibitor

Publications (2)

Publication Number Publication Date
EP3941467A1 EP3941467A1 (en) 2022-01-26
EP3941467A4 true EP3941467A4 (en) 2022-12-21

Family

ID=72520501

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20772952.6A Pending EP3941467A4 (en) 2019-03-19 2020-03-19 Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1 and/or pd-l1 inhibitor

Country Status (2)

Country Link
EP (1) EP3941467A4 (en)
WO (1) WO2020191240A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2915810A1 (en) * 2012-11-01 2015-09-09 The Second Military Medical University, PLA N-(5-(quinolin-6-yl)pyridin-3-yl) benzsulfamide derivatives, preparation method and therapeutic use thereof
WO2016100561A2 (en) * 2014-12-16 2016-06-23 Bristol-Myers Squibb Company Use of immune checkpoint inhibitors in central nervous systems neoplasms
US20190269664A1 (en) * 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
US20190275015A1 (en) * 2017-09-25 2019-09-12 Chemocentryx, Inc. Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1575918A2 (en) * 2002-12-19 2005-09-21 Neurogen Corporation Substituted biaryl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators
CA2940470C (en) * 2015-09-18 2019-08-20 Signpath Pharma Inc. Treatment for glioblastoma
US10195188B2 (en) * 2016-06-13 2019-02-05 Chemocentryx, Inc. Method of treating pancreatic cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2915810A1 (en) * 2012-11-01 2015-09-09 The Second Military Medical University, PLA N-(5-(quinolin-6-yl)pyridin-3-yl) benzsulfamide derivatives, preparation method and therapeutic use thereof
WO2016100561A2 (en) * 2014-12-16 2016-06-23 Bristol-Myers Squibb Company Use of immune checkpoint inhibitors in central nervous systems neoplasms
US20190275015A1 (en) * 2017-09-25 2019-09-12 Chemocentryx, Inc. Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
US20190269664A1 (en) * 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHER L MORTON ET AL: "Evaluation of ABT-751 against childhood cancer models in vivo", INVESTIGATIONAL NEW DRUGS, KLUWER ACADEMIC PUBLISHERS, BO, vol. 25, no. 4, 24 March 2007 (2007-03-24), pages 285 - 295, XP019500046, ISSN: 1573-0646, DOI: 10.1007/S10637-007-9042-Y *
See also references of WO2020191240A1 *

Also Published As

Publication number Publication date
EP3941467A1 (en) 2022-01-26
WO2020191240A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
EP3687525A4 (en) Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
EP4034094A4 (en) Phosphodiesterase inhibitors and use
EP3817580A4 (en) Cartridge and aerosol generating device including the same
EP4059928A4 (en) Rock inhibitor, preparation method therefor and use thereof
EP3915992A4 (en) Pde9 inhibitor and use thereof
EP3893891A4 (en) Solid forms of a cd73 inhibitor and the use thereof
GB201910547D0 (en) Pressure-sensitive sheet and modular system inculding the same
EP3999513A4 (en) Adenosine a2a receptor antagonists and uses thereof
EP3848377A4 (en) Fgfr4 inhibitor and use thereof
IL280831A (en) Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors
EP4006238A4 (en) Site management system and work machine
EP3866622A4 (en) Cartridge and aerosol generating device including the same
EP3911331A4 (en) Tetrazolone substituted steroids and use thereof
EP3941467A4 (en) Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1 and/or pd-l1 inhibitor
IL288085A (en) Expression systems for the alpha 9/alpha 10 nicotinic acetylcholine receptor and methods of use thereof
EP3982765A4 (en) Aerosol delivering device and aerosol generating device including the same
EP3941909A4 (en) Pi4-kinase inhibitors and methods of using the same
EP3982968A4 (en) Hdac3 catalytic inhibitor development and uses thereof
EP3931565A4 (en) Methods and agents for assessing t-cell function and predicting response to therapy
EP4017857A4 (en) Mettl16 inhibitors and uses thereof
EP4038072A4 (en) Mcl1 inhibitors and uses thereof
EP3986856A4 (en) Compositions and methods for treating cannabinoid hyperemesis syndrome with a cannabinoid receptor antagonist
EP3953342A4 (en) Improved inhibitors of the notch transcriptional activation complex and methods for use of the same
EP4077325A4 (en) Selective cdk4/6 inhibitor cancer therapeutics
EP4025564A4 (en) Nitrification inhibitors

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211015

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40060795

Country of ref document: HK

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031441800

Ipc: A61K0031444000

A4 Supplementary search report drawn up and despatched

Effective date: 20221118

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20221114BHEP

Ipc: A61K 39/395 20060101ALI20221114BHEP

Ipc: A61K 31/519 20060101ALI20221114BHEP

Ipc: C07K 16/28 20060101ALI20221114BHEP

Ipc: A61P 35/00 20060101ALI20221114BHEP

Ipc: A61K 31/444 20060101AFI20221114BHEP

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED

Owner name: CHEMOCENTRYX, INC.